Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal Influenza Vaccine with Imiquimod in Non-responsive Children
NCT05315024Unknown
- Sponsor
- The University of Hong Kong
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
01
Overview
Randomised, open-label trial of imiquimod in influenza (3 arms), sponsored by The University of Hong Kong. Primary endpoint: Seroconversion rates at 2 years. Status: unknown.
02
Drugs
imiquimod
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05315024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05315024.